On Friday’s MedHeads, reporters Neil Versel and Meghana Keshavan joined Digital Health Editor Stephanie Baum to discuss issues addressed at the RESI conference, a bubble brewing in the biotech sector and fallout over health IT costs.
Watch the broadcast above, but also review five important topics we looked at this week.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
1. What issues draw the most attention in FDA medical device inspections?
As a medical device company, you do know that an FDA inspection will happen, right?
FDA is supposed to inspect all medical device companies with class II (and higher) devices at least every two years.
2. American Well sues Teladoc over telehealth intellectual property
Telehealth company American Well has sued competitor Teladoc, claiming infringement of intellectual property rights.
In a suit filed Monday in federal court in Boston, American Well accuses Teladoc of infringing a patent for technology that connects consumers to telehealth service providers.
3. Five (non-cancer) areas Bristol-Myers Squibb is pursuing hard
Outside of cancer immunotherapy, Bristol-Myers Squibb is interested in pursuing five areas: Heart failure, virology, rare disease, immunoscience and fibrosis.
Donnie McGrath, a vp at Bristol-Myers Squibb and head of search and evaluation, discussed business development strategy in an interview at this week’s Redefining Early Stage Investments (RESI) conference in Houston.
4. “Internet of Me,” outcomes headline Accenture health IT trends (infographic)
Accenture has come out with its annual list of trends in health IT, and it’s safe to say the research and consulting firm is looking far beyond Meaningful Use.
In some ways it’s a bit of wishful thinking. “The healthcare IT leaders of today are doing more than just talking a good digital game. They are fundamentally changing the way technology is used for care delivery. Healthcare consumers, providers and payers are embracing the transformational power of technology, and it’s paying off in unprecedented efficiency and effectiveness across the care ecosystem,” Accenture says in the overview to its graphics-intensive report.
5. A growing problem for healthcare startups seeking investment: (Almost) no one wants to lead
It’s early on at today’s Redefining Early Stage Investments (RESI) Conference in Houston. But here’s one phrase I’ve already heard too often: We don’t lead.
Anyone in any sector that’s tried to raise capital has heard that phrase — sometimes for good reasons. But it’s going to be heard too often as healthcare investing continues to evolve.
